| Study |
Reference |
|
Broms (Controls exposed to other treatments), 2020
|
Broms Anti-TNF treatment during pregnancy and birth outcomes: A population-based study from Denmark, Finland, and Sweden. Pharmacoepidemiol Drug Saf 2020; 29:316-327
|
|
Broms (Controls unexposed, disease free), 2020
|
Broms Anti-TNF treatment during pregnancy and birth outcomes: A population-based study from Denmark, Finland, and Sweden. Pharmacoepidemiol Drug Saf 2020; 29:316-327
|
|
Bröms (controls unexposed, disease free), 2016
|
Bröms G Low Risk of Birth Defects for Infants Whose Mothers Are Treated With Anti-Tumor Necrosis Factor Agents During Pregnancy Clin Gastroenterol Hepatol. 2016a;14(2):234-241
|
|
Bröms (controls unexposed, sick), 2016
|
Bröms G Low Risk of Birth Defects for Infants Whose Mothers Are Treated With Anti-Tumor Necrosis Factor Agents During Pregnancy Clin Gastroenterol Hepatol. 2016a;14(2):234-241
|
|
Carman (Control unexposed, disease free), 2017
|
Carman WJ Pregnancy and infant outcomes including major congenital malformations among women with chronic inflammatory arthritis or psoriasis, with and without etanercept use. Pharmacoepidemiol Drug Saf 2017;26:1109-1118
|
|
Carman (Control unexposed, sick), 2017
|
Carman WJ Pregnancy and infant outcomes including major congenital malformations among women with chronic inflammatory arthritis or psoriasis, with and without etanercept use. Pharmacoepidemiol Drug Saf 2017;26:1109-1118
|
|
Chambers, 2015
|
Chambers Pregnancy Outcome in Women Treated with Etanercept: An Update on the OTIS Autoimmune Diseases in Pregnancy Project Pharmacoepidemiology and Drug Safety 2015; 24:402–402
|
|
De Lorenzo (Controls unexposed, disease free), 2020
|
De Lorenzo Neonatal outcomes of children born to mothers on biological agents during pregnancy: State of the art and perspectives. Pharmacol. Res. 2020; 152:104583
|
|
De Lorenzo (Controls unexposed, sick), 2020
|
De Lorenzo Neonatal outcomes of children born to mothers on biological agents during pregnancy: State of the art and perspectives. Pharmacol. Res. 2020; 152:104583
|
|
Drechsel, 2020
|
Drechsel Pregnancy outcomes in DMARD-exposed patients with juvenile idiopathic arthritis-results from a JIA biologic registry. Rheumatology (Oxford) 2020; 59:603-612
|
|
Fu, 2019
|
Fu A randomized controlled trial of etanercept in the treatment of refractory recurrent spontaneous abortion with innate immune disorders. Taiwan J Obstet Gynecol 2019; 58:621-625
|
|
Hoxha, 2017
|
Hoxha A Pregnancy and foetal outcomes following anti-tumor necrosis factor alpha therapy: A prospective multicentre study. Joint Bone Spine 2017;84:169-173
|
|
Hyrich, 2006
|
Hyrich Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: results from a national population register. Arthritis Rheum. 2006; 54:2701-2
|
|
Langen, 2014
|
Langen High rate of preterm birth in pregnancies complicated by rheumatoid arthritis. Am J Perinatol 2014; 31:9-14
|
|
Viktil (Controls exposed to other treatments), 2012
|
Viktil Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150,000 pregnant women and expectant fathers. Scand J Rheumatol 2012; 41:196-201
|
|
Viktil (Controls unexposed, NOS), 2012
|
Viktil Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150,000 pregnant women and expectant fathers. Scand J Rheumatol 2012; 41:196-201
|
|
Vinet (Unexposed controls, disease free), 2018
|
Vinet E Serious Infections in Rheumatoid Arthritis Offspring Exposed to Tumor Necrosis Factor Inhibitors: A Cohort Study. Arthritis Rheumatol 2018;70:1565-1571
|
|
Vinet (Unexposed controls, sick), 2018
|
Vinet E Serious Infections in Rheumatoid Arthritis Offspring Exposed to Tumor Necrosis Factor Inhibitors: A Cohort Study. Arthritis Rheumatol 2018;70:1565-1571
|
|
Weber-Schoendorfer, 2015
|
Weber-Schoendorfer C Pregnancy outcome after TNF-? inhibitor therapy during the first trimester: a prospective multicentre cohort study. Br J Clin Pharmacol 2015;80:727-39
|
